In a patient with depression and anxiety who reports lack of motivation and inability to complete tasks while taking bupropion 75 mg daily and buspirone 5 mg twice daily, what medication adjustment should be made?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Increase Bupropion Dose to 150mg Daily

Your patient is on subtherapeutic doses of both medications—the most appropriate adjustment is to increase bupropion to 150mg daily (the minimum therapeutic dose for depression) and consider increasing buspirone to 15-30mg daily in divided doses. The current bupropion dose of 75mg is below the therapeutic range for major depressive disorder, and buspirone at 5mg twice daily (10mg total) is also subtherapeutic for anxiety.

Rationale for Dose Optimization

Bupropion Dosing

  • Current dose (75mg) is subtherapeutic: The FDA-approved therapeutic range for bupropion in depression is 150-450mg daily 1
  • Target dose: Start with 150mg daily (the minimum effective dose), which can be increased to 300mg daily if needed 2
  • Bupropion at 300mg daily has demonstrated efficacy for recurrent major depression 3
  • The medication is "activating" and specifically noted to reduce apathy and improve energy levels 2—directly addressing your patient's lack of motivation

Buspirone Dosing

  • Current dose (10mg/day total) is subtherapeutic: Therapeutic dosing for anxiety typically requires 20-60mg daily 2
  • Target dose: Increase to 15mg twice daily (30mg total), with potential titration to 20mg three times daily (60mg total) if needed 2
  • Buspirone takes 2-4 weeks to become effective, so patience is required 2
  • Evidence supports buspirone's efficacy in depression with comorbid anxiety at doses up to 90mg/day 4, 5

Evidence Supporting This Approach

Bupropion for Motivation and Task Completion

Bupropion is specifically characterized as "activating" with "possible rapid improvement of energy level" 2. This makes it particularly well-suited for patients presenting with lack of motivation and inability to complete tasks. The dopamine-norepinephrine reuptake inhibition mechanism directly targets the motivational deficits your patient describes 6.

Addressing Anxiety Concerns with Bupropion

While bupropion has historically been viewed with caution in anxious patients 2, recent evidence challenges this concern:

  • Low-certainty evidence suggests bupropion provides clinically relevant improvement in anxiety symptoms in adults with MDD 7
  • Multiple studies show comparable efficacy to SSRIs for mild-to-moderate anxiety in depressed patients 7, 8
  • None of the reviewed studies reported clear signals of anxiety worsening on validated anxiety measures 7
  • The "activating" effect can be managed by starting low and titrating slowly 2

Buspirone Augmentation Evidence

Buspirone has demonstrated efficacy both as monotherapy and augmentation:

  • 59% response rate when added to SSRIs in treatment-resistant depression 9
  • Significant improvement in both anxiety and depressive symptoms in patients with GAD and mild depression 5
  • Recent 2025 data shows HAMA scores decreased from 25.2 to 15.4 over 12 weeks with buspirone augmentation 10
  • Well-tolerated with only 3.7% adverse event rate 10

Practical Implementation Algorithm

Week 1-2:

  • Increase bupropion from 75mg to 150mg daily (take in morning to minimize insomnia risk) 1
  • Increase buspirone from 5mg BID to 7.5mg BID (15mg total daily)
  • Monitor for anxiety, agitation, or insomnia

Week 3-4:

  • If tolerated but insufficient response, increase buspirone to 10mg BID (20mg total)
  • Continue bupropion at 150mg

Week 6-8:

  • Assess response using standardized measures
  • If partial response with good tolerability, consider:
    • Increasing bupropion to 300mg daily (maximum for XL formulation) 1
    • Increasing buspirone to 15mg BID or 20mg TID (30-60mg total) 2

Week 12:

  • Full therapeutic trial complete
  • If inadequate response (<30% improvement), consider switching strategies per guidelines 11, 12

Critical Safety Considerations

Bupropion Warnings

  • Seizure risk: Dose-dependent; do not exceed 300mg daily with XL formulation 1
  • Contraindications: Seizure disorder, eating disorders, abrupt benzodiazepine/alcohol discontinuation 1
  • Monitor for: Suicidal ideation (especially first weeks), behavioral activation, insomnia 1
  • Drug interactions: Inhibits CYP2D6—caution with other antidepressants, antipsychotics, beta-blockers 1

Buspirone Considerations

  • Takes 2-4 weeks for anxiolytic effect—counsel patient on delayed onset 2
  • Generally well-tolerated; main side effects are dizziness and nausea
  • No significant drug interactions with bupropion
  • Can be taken with or without food

Why Not Alternative Strategies?

Adding an SSRI: Would be premature before optimizing current regimen. Guidelines support augmentation strategies only after adequate trials of first-line agents 11, 12. Your patient hasn't had a therapeutic trial of either current medication.

Switching entirely: The STAR*D trial showed no significant differences between various switch strategies 11, 12. Optimizing current medications is more conservative and evidence-based before switching.

Combination therapy from guidelines: The evidence you provided focuses on obesity management (naltrexone-bupropion) 3 or pediatric anxiety 13—not applicable to your adult patient with depression/anxiety.

Common Pitfall to Avoid

The most common error is abandoning medications before reaching therapeutic doses. Both bupropion and buspirone are currently at subtherapeutic levels. The 2002 guideline explicitly states that dose increases should occur "every 5 to 7 days until therapeutic benefits or significant side effects become apparent" 2. Your patient deserves an adequate therapeutic trial before considering more complex interventions.

References

Research

Buspirone in depressed outpatients: a controlled study.

Psychopharmacology bulletin, 1990

Research

Bupropion and Anxiety: A Brief Review.

Human psychopharmacology, 2025

Research

Buspirone augmentation of antidepressant therapy.

Journal of clinical psychopharmacology, 1998

Research

Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2025

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Related Questions

Patient with major depressive disorder and anxiety, currently taking bupropion XL 450 mg daily, gabapentin 600 mg three times daily, quetiapine 50 mg three times daily, and as‑needed hydroxyzine, can buspirone be added?
I have major depressive disorder and generalized anxiety disorder and am taking duloxetine 60 mg daily and buspirone 7.5 mg twice daily, but my anxiety has worsened; what should I do?
I have depression and anxiety and am taking escitalopram (Lexapro) and buspirone (Buspar); I am still experiencing anxiety—what adjustments should be made?
A 40-year-old female with a history of depression and anxiety is currently taking Wellbutrin (bupropion) XL 300 mg once daily, Buspar (buspirone) 15 mg twice daily, and sertraline 50 mg once daily. What medication recommendations are appropriate?
Is it appropriate to start Buspirone (Buspar) together with bupropion (Wellbutrin) in a patient who requires both anxiolytic and antidepressant therapy, and what dosing and monitoring should be used?
How does eating liver improve skin and hair health?
Should a patient with an extensive deep vein thrombosis (DVT) go to the emergency department (ED)?
After an amputation surgery, how many days can I safely discontinue Eliquis (apixaban) for venous thromboembolism prophylaxis?
During what gestational age window can a medical abortion kit (mifepristone followed by misoprostol) be administered?
Can you provide a SOAP note with appropriate CPT and ICD‑10 codes for a 50‑year‑old female presenting with aphthous oral ulcers, tongue swelling, throbbing pain, weight loss due to difficulty eating, white‑yellow exudate on gums and lateral tongue, who is allergic to penicillin and has a history of type 2 diabetes with neuropathy, hypertension, hyperlipidemia, anxiety, and depression?
Is it safe to take loratadine 10 mg with Mucinex (guaifenesin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.